Bioceltix S.A. (WSE:BCX)

Market Cap	381.17M -20.2%
Revenue (ttm)	n/a
Net Income	-18.52M
EPS	-3.49
Shares Out	5.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,420
Open	69.00
Previous Close	68.30
Day's Range	68.20 - 69.50
52-Week Range	57.50 - 99.50
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Bioceltix

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company’s products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 49
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BCX

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 4, 2026

Data Sources Report a data error